Background: Polycystic ovary syndrome (PCOS) is a common ovulatory disorder that can be induced by sodium valproate (VPA).
Introduction
Polycystic ovary syndrome (PCOS) is known to occur more frequently in women taking sodium valproate (VPA) for epilepsy than in the general female population 1 . The symptoms of PCOS include menstrual disorders (including amenorrhea), infertility, miscarriage, and hirsutism 2 . PCOS is characterized by any 2 of the following: oligomenorrhea or amenorrhea, hyperandrogenism or hyperandrogenemia, and polycystic ovaries 2, 3 . The diagnostic criteria for PCOS define hyperandrogenemia as elevated serum total testosterone, free testosterone, or androstenedione levels 3 .
The purpose of this case report is to highlight the problem of PCOS induced by VPA to medical staff treating patients with epilepsy.
Case Report
The patient was a 15-year-old girl who had been born uneventfully at 40 weeks of gestation weighing 3,060 g.
There was no family history of neurological disorders or epilepsy, and her developmental milestones were normal, although she experienced a small number of episodes of febrile seizures in infancy. At the age of 12 years, however, she experienced her first unprovoked generalized tonic-clonic seizure (GTCs) and was brought to our clinic. Electroencephalography (EEG) showed diffuse spikes and wave complexes (SWCs) (Fig. 1) readings were normal, and she had experienced no epileptic seizures since she started taking VPA.
When she reached her menarche at the age of 14 years and 2 months, she was 165 cm in height and weighed 60 kg (BMI: 22.0). She had a regular menstrual cycle of about 4 weeks. When she was 14 years and 9 months old, she was 167 cm tall and weighed 69 kg (BMI: 24.7).
However, neither her health providers, her parents, nor the patient herself paid much attention to her weight gain. There were two reasons for this: her satisfactory clinical course, and the fact that she was focusing on high school entrance examinations.
After she gained admission to high school at the age of 15 years and 7 months (height: 167 cm, weight: 73 kg, BMI: 26.1), her EEG readings were normal (data not shown), and because she had had no seizures for 2 years and 6 months, VPA cessation was considered. At this point, her serum VPA levels had increased from 80 to 90 μg/mL, and she revealed that she had not menstruated for several months. A growth curve created around the same time also showed clear weight gain in the patient since the start of VPA administration (Fig. 2) . This new clinical information led to suspicion of PCOS.
Ultrasonography and MRI of the abdomen showed multiple cysts in her ovaries (Fig. 3-A, 3-B) . Her luteinizing hormone level was high (9.1 mIU/mL), and her follicle stimulating hormone level was normal (5.3 mIU/mL).
Her total-testosterone (1.17 ng/mL) and free-testosterone (1.3 pg/mL) were within normal limits. Adrenal function was also within normal limits, as were her insulin level, blood glucose level, and lipid metabolism (data not shown). These finding met the diagnostic criteria for PCOS 3 . As soon as the diagnosis was confirmed, the dosage of VPA was reduced by 50% for 1 month, after which administration was terminated. The patient lost weight gradually and, 2 months after VPA cessation, menstruation resumed (Fig. 2) .
Discussion
First reported in 1935 4 , PCOS is a common ovulatory disorder estimated to affect 5% to 10% of the female population 5, 6 . The risk of developing PCOS during VPA treatment is reportedly higher in women with epilepsy than in women with bipolar disorders, which may be due to an underlying neuroendocrine dysfunction related to seizure disorders 7 . Indeed, it has been reported that epileptic discharge itself may affect hypothalamic function via dysregulation of gonadotropin-releasing hormone pulse generators 8 . Other evidence shows that the incidence of PCOS is more common among women with epilepsy 9 .
An association between the development of PCOS and all antiepileptic drugs (AEDs) is suspected, but it has been reported that PCOS develops more frequently in patients administered with VPA than in those taking any other medication for epilepsy 10, 11 .
PCOS has reproductive, metabolic, and cardiovascular components 2 . According to Ehermann, Androgen excess and insulin resistance, both of which have strong genetic components, underlie much of the clinical presentation 2 .
The insulin resistance of PCOS appears to impart an increased risk of glucose intolerance, diabetes, and lipid abnormalities, and may enhance the development of vascular disease 12 15 . These metabolic abnormalities may have an indirect influence on reproductive functions, however, the detailed pathophysiology of PCOS remains unknown.
Other researchers have reported that stopping VPA administration leads to recovery of the menstrual cycle 16, 17 , so VPA cessation may be the best option for patients who develop PCOS.
In 2015, an International League Against Epilepsy task force recommended that restrictions on the use of VPA in women and girls be strengthened 18 . Separately, lamotrigine has been reported to be a viable substitute for VPA 19 .
Since the 1990s, VPA has been used to treat patients in a manic state 20 , and it has also been presented as an op- Fig. 2 Growth curve Between the ages of 12 and 17 years, the patient's height ranged between 1 and 2 standard deviations above the mean height for her age group. However, her weight during sodium valproate (VPA) administration increased to over 2 standard deviations above the mean. It then decreased again after VPA administration was discontinued. The outline arrow indicates the start of VPA administration (patient's age: 13 years and 1 month), and the black arrow the cessation of VPA (15 years and 7 months). Pincus therapy should be considered 22 .
Because of the role played by epilepsy itself in the development of PCOS 7 , elucidation of the full pathophysiology of PCOS is eagerly awaited.
